Front of the Eye (Anterior Segment)

Eliot Lazar, M.D.

Eliot Lazar, M.D.

Eliot Lazar, M.D., is a clinical ophthalmologist who serves as the President of elCON Medical Consulting and the Principal of elCON Medical in Buffalo, New York. Dr. Lazar has extensive experience in the commercial side of ophthalmology and other specialties. He has worked broadly in the development of devices, therapeutics, and diagnostics, and has participated in many of the critical drug delivery advances in ophthalmology and other specialties. Dr. Lazar has also collaborated with financial institutions of all sizes and scopes on both due diligence as well as at the board of directors level. Dr. Lazar has worked collaboratively with both local and global organizations on endeavors from the pre-clinical stage through the commercial stage. Dr. Lazar holds a B.S. from the University of Pennsylvania, an M.S. in Immunology from the Royal College of Surgeons, Trinity College, and the State University of New York, and an M.D. from Georgetown University School of Medicine.

Gerald Horn, M.D.

Gerald Horn, M.D.

Gerald Horn, M.D., the original inventor of Nyxol®, is a board-certified ophthalmologist and laser vision specialist. A pioneer in his field, Dr. Horn has dedicated his career to laser vision surgery and is trained in numerous procedures, including LASIK. Dr. Horn received his undergraduate degree from Northwestern University and his medical degree in ophthalmology from the University of Illinois Medical School. He completed an internship at Rush-Presbyterian St. Luke’s Hospital and went on to complete several mini-fellowships in LASIK, radial keratotomy, ALK, and epikeratophakia. His expertise in front-of-the-eye conditions, and passion for drug development led him to develop phentolamine mesylate ophthalmic solution (Nyxol®) and co-found Ocularis Pharma. As the founder and board member at Eye Therapeutics, he invented Lumify®, an extended-use eye whitener licensed to and sold by Bausch & Lomb. As the Chief Scientific Officer at Presbyopia Therapies, Dr. Horn invented “Liquid Vision,” an eye drop designed to temporarily restore reading vision with a recent successful Phase 2b FDA trial. As the Chief Scientific Officer at PS Therapies, he is developing a topical contact lens blister pack and disruptive OTC dry eye therapy formulations. Dr. Horn is an author on numerous patents covering a range of ophthalmic drugs and OTC products.

Jay Pepose, M.D., Ph.D.

Jay Pepose, M.D., Ph.D.

Jay S. Pepose, M.D., Ph.D., FARVO, is the founder and Medical Director of the Pepose Vision Institute andthe Midwest Corneal Research Foundation. He is Professor of Clinical Ophthalmology and Visual Sciences at Washington University School of Medicine in St. Louis, where he held the Bernard Becker Chair. Dr. Peposeis a clinical specialist in lens and corneal based refractive surgery and corneal and external diseases, and has served as consultant to the Centers for Disease Control and Prevention. Dr. Pepose is actively involved in clinical research trials and has been the recipient of R-01 grant support from the National Eye Institute. Dr. Pepose has served as Executive Editor of the American Journal of Ophthalmology, as well as on the editorial board of Investigative Ophthalmology & Visual Science (IOVS), Cornea, and The Journal of Refractive Surgery. Dr. Pepose has published over 200 peer-reviewed articles and a book on ocular infections and inflammatory diseases. He is recipient of the Cogan Award from ARVO and the Life Achievement Honor Award from the American Academy of Ophthalmology Dr. Pepose received an A.B. and M.A. in neurophysiology from Brandeis University and completed the M.D./Ph.D. program at the UCLA School of Medicine. He completed his ophthalmology residency at the Wilmer Institute at the Johns Hopkins Medical Center and his fellowship training at Georgetown University Medical Center.

Marguerite McDonald, M.D., F.A.C.S.

Marguerite McDonald, M.D., F.A.C.S.

Marguerite McDonald, M.D., F.A.C.S., is a board-certified ophthalmologist. She received her medical degree from Columbia University College of Physicians and Surgeons and completed her internship at Lenox Hill Hospital, ophthalmology residency at Manhattan Eye Ear and Throat Hospital/Cornell, and a fellowship in corneal and external diseases at the LSU Eye Center. From 1993 to 2005, Dr. McDonald served as the director of the Southern Vision Institute in New Orleans. She is a clinical professor of ophthalmology at the NYU School of Medicine and an clinical professor of ophthalmology at Tulane University Health Sciences Center. Dr. McDonald was a professor of ophthalmology and the director of the Corneal Service at the LSU Eye Center, LSU Medical Center School of Medicine. She performed the world’s first excimer laser treatment to eliminate or reduce the need for glasses and contact lenses as well as the world’s first excimer laser surgeries for farsightedness. She was also the first North American surgeon to perform Epi-LASIK. Dr. McDonald also performed the first EBK procedure (epi-Bowman’s keratectomy) in the Americas. Dr. McDonald has over 1,800 publications, has received many awards, and has served on the editorial boards of several publications, including the Journal of Cataract and Refractive Surgery and the Journal of Refractive Surgery. She was elected the first female president of the American Society of Cataract and Refractive Surgery (ASCRS) for the 2002-03 term. In 2009-10, Dr. McDonald served as the first female president of the International Society of Refractive Surgery of the American Academy of Ophthalmology (ISRS/AAO).

Edward Holland, M.D.

Edward Holland, M.D.

Edward Holland, M.D., is the Director of Cornea Services at Cincinnati Eye Institute and a professor of ophthalmology at the University of Cincinnati. Dr. Holland is internationally known for his knowledge and expertise in the field of cornea and external diseases. Dr. Holland is the author of over 270 articles in peer-reviewed journals and has co-edited four editions of Cornea, the most widely read textbook on corneal disease and surgery. He attended the Loyola-Medical School in Chicago and trained in Ophthalmology at the University of Minnesota. He completed a fellowship in cornea and external disease at the University of Iowa, and then a second fellowship in ocular immunology at the National Eye Institute. Dr. Holland was a former member of the Board of Trustees for the American Academy of Ophthalmology and received both the Senior Achievement Award and Life Achievement Honor Award from the AAO. He also served as the President of American Society of Cataract and Refractive Surgery and presently serves as the Program Chair.

Richard Lindstrom, M.D.

Richard Lindstrom, M.D.

Richard L. Lindstrom, M.D., is a board-certified ophthalmologist and internationally-recognized leader in corneal, cataract, refractive and laser surgery. Dr. Lindstrom is the founder of and attending surgeon at Minnesota Eye Consultants, an adjunct professor emeritus and Foundation Trustee at the University of Minnesota, and Visiting Professor at the UC Irvine Gavin Herbert Eye Institute. He has been at the forefront of ophthalmology’s evolutionary changes throughout his career, as a recognized researcher, teacher, inventor, investor, writer, lecturer and highly-acclaimed physician and surgeon. After graduating magna cum laude from the College of Liberal Arts at the University of Minnesota, Dr. Lindstrom completed his doctorate degree in medicine in 1972. Dr. Lindstrom holds over 40 patents in ophthalmology and has developed a number of solutions, intraocular lenses and instruments that are used in clinical practice globally. Dr. Lindstrom is a frequent lecturer on cornea, external disease, cataract IOL, refractive surgery, and glaucoma. He has presented over 40 named lectures and keynote speeches at Universities and Professional Societies throughout the world. He has co-edited ten books, published over 400 peer-reviewed journal articles and written 60 book chapters.

Jack Holladay, M.D., MSEE, F.A.C.S.

Jack Holladay, M.D., MSEE, F.A.C.S.

Jack T. Holladay, M.D., M.S.E.E., F.A.C.S., is a board-certified ophthalmologist and a clinical professor of ophthalmology at Baylor College of Medicine. Dr. Holladay has authored three books and hundreds of chapters and articles in peer-reviewed scientific journals. He serves on several editorials, medical, and scientific advisory boards, and holds numerous patents. Dr. Holladay was inducted into the Hall of Fame of the American Society of Cataract and Refractive Surgery in 2012. He is currently the Chair of the FDA/American Academy of Ophthalmology Task Force charged with developing guidelines for accommodating and extended depth of focus (EDOF) intraocular lenses (IOLs). Dr. Holladay received his medical degree and the Distinguished Alumnus Award from the University of Texas and his bachelor’s and master’s degrees in Electrical Engineering from Southern Methodist University.

Paul Karpecki, O.D., FAAO

Paul Karpecki, O.D., FAAO

Dr. Karpecki received his doctor of optometry degree from Indiana University and completed a fellowship in Cornea in Kansas City in affiliation with the Pennsylvania College of Optometry.  He currently serves as Director of Cornea Services for Kentucky Eye Institute in Lexington KY, Gaddie Eye Centers in Louisville KY, Midwest Center for Sight in Carmel IN.  He is the Chief Medical Editor for Review of Optometry, chairman of the NTT Conferences and heads the journal’s clinical content.  He is Medical Director for KEPLR Vision and for the Dry Eye Institutes of Kentucky and Indiana.  He was appointed co-chair for the previous two Tear Film and Ocular Surface Society Symposia and served on the DEWS II Diagnostic Methodology Committee.  In 2017-2018 he completed a full year preceptorship in advanced retinal disease at Retina Associates of Kentucky, one of the top 20 retina programs in the country. He currently serves as an Associate Professor at the Kentucky College of Optometry and on the board for the charitable organization Optometry Giving Sight.

Thomas W. Samuelson, M.D.

Thomas W. Samuelson, M.D.

Thomas W. Samuelson, M.D., is a board-certified ophthalmologist who specializes in the treatment of glaucoma, cataract, and refractive surgery, as well as a founding partner and attending surgeon of Minnesota Eye Consultants. Dr. Samuelson completed his medical degree at the University of Minnesota, his residency training at the University of South Florida where he served as chief resident, and his sub-specialty training at the Wills Eye Hospital in Philadelphia. Dr. Samuelson is an adjunct professor of ophthalmology at the University of Minnesota and past chairman of the medical staff at the Phillips Eye Institute in Minneapolis. Dr. Samuelson was previously president of the American Society of Cataract and Refractive Surgery. He is the recipient of the American Academy of Ophthalmology’s Junior and Senior Achievement Awards honoring contributions made to the Academy’s educational programs. In 2018, Dr. Samuelson was awarded the AAO Lifetime Achievement Award. He also received the “Secretariate Award” for contributions to the AAO annual meeting. Dr. Samuelson has served as an examiner for the American Board of Ophthalmology and has been named as one of America’s Top Doctors each year since 2002. Dr. Samuelson served on the executive committee of the American Glaucoma Society for nearly a decade. As a member of the Basic Clinical Science Course Committee for the AAO, Dr. Samuelson helped to write the textbooks most studied by residents within the field of ophthalmology. Dr. Samuelson is the glaucoma section editor for Ocular Surgery News and serves as editorial board member and scientific reviewer for several other ophthalmology journals.

Back of the Eye (Retina)

Mark R. Kelley, Ph.D.

Mark R. Kelley, Ph.D.

Mark R. Kelley, Ph.D., is the Associate Director of Basic Science at Indiana University Simon Comprehensive Cancer Center and the Betty and Earl Herr Professor in Pediatric Oncology Research and Professor, Department of Pediatrics. He is also Professor in Ophthalmology, Biochemistry & Molecular Biology, Pharmacology & Toxicology and Adjunct Professor, Eugene and Marilyn Glick Eye Institute [ add titles including the ophthalmic faculty position]. Dr. Kelley’s work has focused on translational research in DNA damage and repair and redox signaling, specifically, to determine how those activities can be exploited therapeutically to treat cancers and other diseases and protect normal cells from damage. Since 1993, he has focused specifically on the enzyme, Redox effector factor-1/apurinic/apyrimidinic endonuclease 1 (Ref-1 or Ref-1/APE1), a therapeutic target in cancers and other diseases such as diabetic retinopathy (DR), diabetic macular edema (DME) and age-related macular degeneration (AMD). He discovered and has been developing redox-specific inhibitors of Ref-1. He is the Chief Scientific Founder and Officer of Apexian Pharmaceuticals, an integrated drug development company focused on the Ref-1 target platform to produce new therapeutics for DR/DME and other diseases with alterations of similar pathways regulated by Ref-1. Apexian Pharmaceuticals, entered into an agreement with Ocuphire Pharma, granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications. Dr. Kelley has a B.A from DePauw University, M.S. and Ph.D. from Louisiana State University and did a postdoctorate at The Rockefeller University.

David Boyer, M.D.

David Boyer, M.D.

David S. Boyer, M.D., is a board-certified ophthalmologist specializing in the treatment of retinal and vitreous diseases. He is a Senior Partner at Retina-Vitreous Associates Medical Group. Dr. Boyer earned his medical degree at Chicago Medical School, completed his internship and residency at the University of Southern California/Los Angeles County Medical Center, and completed his fellowship in retinal surgery at the Wills Eye Hospital in Philadelphia. Dr. Boyer is a clinical professor of ophthalmology at the Keck School of Medicine of the University of Southern California and has an extensive research background. He is one of the leading retinal clinical researchers in the country for new treatments in macular degeneration and diabetic macular edema. Dr. Boyer is a widely-published author and avid lecturer who lectures internationally on retinal research and innovative approaches to the treatment of retinal disease. He has authored and co-authored numerous works in peer-reviewed journals and has served as a reviewer for ophthalmology and diabetes medical publications, including Archives of Ophthalmology, American Journal of Ophthalmology, and Ophthalmology.

Michael Allingham, M.D., Ph.D.

Michael Allingham, M.D., Ph.D.

Michael Allingham, M.D., Ph.D., is a retina trained clinician scientist with expertise in the diagnosis and treatment of macular diseases including diabetic retinopathy and edema, macular degeneration and retinal vein occlusion. Dr. Allingham attended Duke University where he earned a B.S. in Chemistry with Distinction. He pursued his M.D. / Ph.D. at the University of North Carolina. Upon completing his M.D. / Ph.D., he returned to Duke for his internship, residency in ophthalmology and fellowship in medical retina before accepting a faculty position in the Duke Eye Center Department of Ophthalmology where he is currently Assistant Professor.

Dr. Allingham's research is focused on the development of new therapies and diagnostics for macular diseases and he is particularly interested in mechanisms of vision loss due to macular edema as seen in diabetes and vein occlusion. He is active in basic laboratory research, clinical research focused on computerized analysis of retinal imaging as well as clinical trials for macular diseases. His research has received funding from the National Institutes of Health and he has published over 20 peer reviewed journal articles, reviews and book chapters.

Peter K. Kaiser, M.D.

Peter K. Kaiser, M.D.

Peter K. Kaiser, M.D., is a clinical research expert, serving as Study Chairman of 5 major, multi-center, international clinical trials, and principal investigator in numerous studies for AMD, DR, and other retinal disorders. He is the founder and director of the Digital Optical Coherence Tomography Reading Center (DOCTR), Editor-in-Chief of Retinal Physician, Associate Editor of International Ophthalmology Clinics, and serves on the editorial boards of Retina, Retina Today, and Ocular Surgery News. He is a National Institute of Health (NIH) funded investigator, leading a team involved in the evaluation of vascular biology in age-related macular degeneration and diabetic retinopathy. Dr. Kaiser serves on numerous scientific advisory boards and addresses his research interests as an invited speaker at national and international conferences. He is a major contributor to the medical literature having authored 7 textbooks, and more than 250 peer-reviewed papers, and has been recognized by the American Academy of Ophthalmology and American Society of Retina Specialists with Senior Achievement Awards and is listed as one of the “Best Doctors in America.” Dr. Kaiser graduated magna cum laude with Highest Honors from Harvard College and Harvard Medical School. He completed an ophthalmology residency at the Massachusetts Eye and Ear Infirmary, and a vitreoretinal fellowship at Bascom Palmer Eye Institute before joining the vitreoretinal department of the Cole Eye Institute, Cleveland, Ohio.    

Jeffrey Heier, M.D.

Jeffrey Heier, M.D.

Dr. Heier is the Co-President, Medical Director, Director of the Vitreoretinal Service, and Director of Retina Research at Ophthalmic Consultants of Boston (OCB), one of the largest and most prestigious multi-specialty ophthalmology practices in the United States. He is also on the Executive Board of the Retina Society and the Executive Committee of the American Society of Retina Specialists. He is the Past President of the New England Ophthalmological Society, and is a member of the Macula Society. Dr. Heier has received several awards from the American Academy of Ophthalmology, including the Senior Achievement Award in 2010, the Secretariat Award in 2007, and the Honor Award in 2003. He is also the recipient of the Honor Award and Senior Honor Award from the American Society of Retina Specialists. Dr. Heier is one of the leading retinal clinical researchers in the country for new treatments in exudative and non-exudative macular degeneration, diabetic macular edema, venous occlusive disease, vitreoretinal surgical techniques and instrumentation, and diagnostic imaging of the retina. He is a scientific advisor to several biotechnical or pharmaceutical companies, lectures nationally and internationally, and has authored numerous, peer-reviewed works. Dr. Heier received his medical degree from Boston University, did an internship and residency at Fitzsimons Army Medical Center, and a vitreoretinal fellowship at OCB/Tufts School of Medicine. Dr. Heier served as a physician in a Combat Support Hospital in the Persian Gulf War, where he was awarded a Bronze Star.